Vitrakvi (larotrectinib) was first granted accelerated approval by FDA in November 2018.
Bayer Announces FDA’s First Full Approval of NTRK Inhibitor
Vitrakvi (larotrectinib) was first granted accelerated approval by FDA in November 2018.
You may also like
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.